- €55.40m
- €58.08m
- €8.00m
- 44
- 11
- 67
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.4 | ||
| Price to Tang. Book | 49.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.37% | ||
| Return on Equity | -28.66% | ||
| Operating Margin | -31.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 3.32 | 4.1 | 4.6 | 4.37 | 8 | 13.8 | 14.8 | 21.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Company’s activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
Directors
- Rafael Rosell Costa CHM
- Javier Rivela Rodriguez CEO
- Luis Barcelona Escartin DRC
- Jose Antonio Maestre Alcacer DRC
- Santiago Ramon y Cajal Agueras DRC
- Rafael Lopez Dieguez Gamoneda IND
- Jesus Tejel Gimenez IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 10th, 2007
- Public Since
- December 29th, 2016
- No. of Employees
- 154
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Madrid Stock Exchange- Shares in Issue
- 33,370,529
- Address
- Quiron Dexeus University Hospital, BARCELONA, 08028
- Web
- https://www.panoncology.com/
- Phone
- +34 934097981
- Auditors
- Ernst & Young S.L.
Upcoming Events for PANG
Similar to PANG
1nkemia IUCT SA
Madrid Stock Exchange
Biotechnology Assets SA
Madrid Stock Exchange
ORYZON Genomics SA
Madrid Stock Exchange
FAQ
As of Today at 22:33 UTC, shares in Pangaea Oncology SA are trading at €1.66. This share price information is delayed by 15 minutes.
Shares in Pangaea Oncology SA last closed at €1.66 and the price had moved by -2.92% over the past 365 days. In terms of relative price strength the Pangaea Oncology SA share price has underperformed the FTSE Global All Cap Index by -5.35% over the past year.
The overall consensus recommendation for Pangaea Oncology SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePangaea Oncology SA does not currently pay a dividend.
Pangaea Oncology SA does not currently pay a dividend.
Pangaea Oncology SA does not currently pay a dividend.
To buy shares in Pangaea Oncology SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €1.66, shares in Pangaea Oncology SA had a market capitalisation of €55.40m.
Here are the trading details for Pangaea Oncology SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: PANG
Based on an overall assessment of its quality, value and momentum Pangaea Oncology SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pangaea Oncology SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.38%.
As of the last closing price of €1.66, shares in Pangaea Oncology SA were trading -5.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pangaea Oncology SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pangaea Oncology SA's management team is headed by:
- Rafael Rosell Costa - CHM
- Javier Rivela Rodriguez - CEO
- Luis Barcelona Escartin - DRC
- Jose Antonio Maestre Alcacer - DRC
- Santiago Ramon y Cajal Agueras - DRC
- Rafael Lopez Dieguez Gamoneda - IND
- Jesus Tejel Gimenez - IND